Follow the people · Insider
Robert Charles Jahr
Robert Charles Jahr files insider transactions with the SEC as a chief executive officer of Outlook Therapeutics (OTLK). We hold 1 disclosed purchase or sale filed since 9 July 2025, 1 of them in the last 90 days.
- Files forOTLK
- Disclosed buys and sells1 in all, 1 in the last 90 days
- Last disclosure14 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 July 2025 — 14 August 2026Chief Executive Officer · Outlook Therapeutics (OTLK)4 Form 4 lines · source: SEC Form 4
Everything they disclosed
4 entries, newest first — one per disclosure report, one per Form 4 line- ▲ bought on the open market 151,515 shares of Outlook TherapeuticsSEC Form 414 August 2026Common Stock · traded 14 August 2026 · filed 14 August 2026
- ▲ bought on the open market 151,515 shares of Outlook Therapeutics (a derivative holding)SEC Form 414 August 2026Warrants (right to buy) · traded 14 August 2026 · filed 14 August 2026
- was granted 100,000 shares of Outlook Therapeutics (a derivative holding)SEC Form 423 July 2026Stock Option (Right to Buy) · traded 21 July 2026 · filed 23 July 2026
- was granted 800,000 shares of Outlook Therapeutics (a derivative holding)SEC Form 49 July 2025Stock Option (Right to Buy) · traded 1 July 2025 · filed 9 July 2025
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.